Celcuity reports phase 1b prostate cancer trial results
Celcuity Inc. (CELC) reported Phase 1b/2 trial results for gedatolisib combined with darolutamide in metastatic castration-resistant prostate cancer. The study showed median radiographic progression-free survival of 15.7 months for patients who received prior abiraterone and 9.1 months for those who received prior enzalutamide. The company plans to begin the Phase 2 portion of the study in the first half of 2027.
How this was made
The 30-second read
Why it matters
Positive efficacy signals could drive short‑term buying interest, but the early stage and limited safety data temper expectations.
Market read
First disclosure of trial data for a micro‑cap oncology biotech, likely to generate immediate market reaction.
What to watch
Trial size is small (45 patients) and safety signals include rash; regulatory path remains uncertain.
Background
Celcuity (NASDAQ:CELC) announced Phase 1b/2 trial results for its PI3K/mTOR inhibitor gedatolisib combined with darolutamide in metastatic castration‑resistant prostate cancer.
Ticker impact
Celcuity reported Phase 1b/2 trial results showing median rPFS of 15.7 months and PSA response rates up to 67% across dose levels.
likely upside as market prices in the encouraging efficacy signals
Phase 1b results are the first disclosure of efficacy; biotech stocks typically react positively to such data.
Market effects
May boost sentiment in the oncology biotech sub‑sector.
Limited to U.S. biotech investors.
Modest; primarily relevant to specialty pharma investors.
Counterpoint
Data are early‑stage; efficacy may not translate to later phases, so caution is warranted.
Key entities
- companyCelcuity Inc.
Biotech firm developing oncology therapies.
